Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
FGI Industries (FGI)
Verdant Earth Technologies (VDNT)
Modular Medical (MODD)
Jupiter Neurosciences, Inc. (JUNS)
Sunfire Acquisition (SUNFU)
Rhodium Enterprises, Inc. (RHDM)
Four Springs Capital Trust (FSPR)
Samsara Vision (SMSA)
Priced IPO
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
Amylyx Pharmaceuticals, Inc. (AMLX)
Cincor Pharma, Inc. (CINC)
Apptech (APCX)
NexGel, Inc. (NXGL)
Immix Biopharma (IMMX)
Bionomics Limited (BNOX)
Genenta Science (GNTA)
Samsara Inc. (IOT)
Sidus Space (SIDU)
Fresh Vine Wine, Inc. (VINE)
Nu Holdings Ltd. (NU)
Hashicorp, Inc. (HCP)
NeuroSense Therapeutics Ltd. (NRSN)
Cingulate, Inc. (CING)
Chicago Atlantic Real Estate Finance, Inc. (REFT)
More companies

Intensity Therapeutics (INTS)

Sector - Healthcare

IPO Profile

About company

Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Their new approach involves the direct injection into tumors of a unique product created from their DfuseRx discovery platform. One challenge that they have identified with current intratumoral (IT) treatment approaches is that a tumor’s lipophilic, high fat and pressurized microenvironment does not effectively absorb water-based products. They believe that this drug delivery challenge limits the effectiveness of prior and current IT treatments that formulate their product candidates by injecting aqueous products (regardless of the mechanism or approach, i.e. the stimulation of an inflammatory response or efforts to attract immune cells into a hostile live tumor). Accordingly, there remains a continued unmet need for the development of direct IT therapies for solid tumors that provide high local killing efficacy coupled with nontoxic systemic anti-cancer effects. They believe they have created a product candidate with the necessary chemistry to overcome this local delivery challenge. Evidence shows the mechanism of tumor killing achieved by their drug candidate also leads to systemic immune activation in certain cancers.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
15 2012

Contacts

Address: 61 Wilton Road, 3rd Floor Westport, Ct 06880

Telephone: (203) 221-7381

Web page: http://www.intensitytherapeutics.com

IPO information

Expected Date 12/6/2021
Status  ! Week of
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 1.5
Shares Revised (MM) -
Expected offer amount (MM) $17
Realized offer amount(MM) -

Financial Data (last reporting year)

Market Cap (MM) $183.0
Revenues (MM) $0
Net Income (Loss) (MM) $-7.13

Voting

What do you think will happen with the INTS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: A.G.P.

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
A.G.P.
CO-Managers
Brookline Capital Markets

Sector: Healthcare

Tweets about $INTS

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats